High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis.

Abstract

BACKGROUND:

Macrophages contribute to the progression and acute complications of atherosclerosis. Macrophage imaging may serve as a biomarker to identify subclinical inflamed lesions, to predict future risk, and to aid in the assessment of novel therapies.

METHODS AND RESULTS:

To test the hypothesis that nanoparticle-enhanced, high-resolution magnetic resonance imaging (MRI) can measure plaque macrophage accumulation, we used 3-T MRI with a macrophage-targeted superparamagnetic nanoparticle preparation (monocrystalline iron oxide nanoparticles-47 [MION-47]) in cholesterol-fed New Zealand White rabbits 6 months after balloon injury. In vivo MRI visualized thickened abdominal aortas on both T1- and T2-weighted spin-echo images (T1 spin echo, 20 axial slices per animal; T2 spin echo, 28 slices per animal). Seventy-two hours after MION-47 injection, aortas exhibited lower T2 signal intensity compared with before contrast imaging (signal intensity ratio, aortic wall/muscle: before, 1.44 ± 0.26 versus after, 0.95 ± 0.22; 164 slices; P<0.01), whereas T1 spin echo images showed no significant change. MRI on ex vivo specimens provided similar results. Histological studies colocalized iron accumulation with immunoreactive macrophages in atheromata. The magnitude of signal intensity reduction on T2 spin echo in vivo images further correlated with macrophage areas in situ (150 slices; r=0.73). Treatment with rosuvastatin for 3 months yielded diminished macrophage content (P<0.05) and reversed T2 signal intensity changes (P<0.005). Signal changes in rosuvastatin-treated rabbits correlated with reduced macrophage burden (r=0.73). In vitro validation studies showed concentration-dependent MION-47 uptake by human primary macrophages.

CONCLUSION:

The magnitude of T2 signal intensity reduction in high-resolution MRI after administration of superparamagnetic phagocytosable nanoparticles can assess macrophage burden in atheromata, providing a clinically translatable tool to identify inflamed plaques and to monitor therapy-mediated changes in plaque inflammation.

• Authors: Kunio Morishige, Daniel F Kacher, Peter Libby, Lee Josephson, Peter Ganz, Ralph Weissleder, Masanori Aikawa
• Journal: Circulation (Circulation) Vol. 122 Issue 17 Pg. 1707-15 (Oct 26 2010) ISSN: 1524-4539 [Electronic] United States
• PMID: 20937980 (Publication Type: Evaluation Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Cholesterol, Dietary
• Fluorobenzenes
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Pyrimidines
• Sulfonamides
• monocrystalline iron oxide nanoparticle
• Rosuvastatin Calcium
• Ferrosoferric Oxide

Topics

• Animals
• Aorta, Abdominal (pathology)
• Atherosclerosis (chemically induced, drug therapy, pathology)
• Cholesterol, Dietary (adverse effects)
• Disease Models, Animal
• Disease Progression
• Ferrosoferric Oxide
• Fluorobenzenes (therapeutic use)
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Macrophages (pathology)
• Magnetic Resonance Imaging (methods)
• Male
• Metal Nanoparticles
• Nanoparticles
• Pyrimidines (therapeutic use)
• Rabbits
• Rosuvastatin Calcium
• Sulfonamides (therapeutic use)
• Treatment Outcome